NCT00477386View on ClinicalTrials.gov

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

September 30, 2013

Conditions
Ovarian Cancer
Interventions
DRUG

decitabine

"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Indiana University

OTHER

NCT00477386 - Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter